Skip to content
  • Mental Health Issues
    • Anxiety
    • ADHD
    • Bipolar Disorder
    • Depression
    • Grief
    • Narcissism
    • OCD
    • Personality Disorders
    • PTSD
    • Anger
    • Burnout
    • Stress
  • Relationships
    • Dating
    • Marriage
    • Sex & Intimacy
    • Infidelity
    • Relationships 101
    • Best Online Couples Counseling Services
  • Quizzes
    • Anxiety Test
    • Depression Test
    • Burnout Test
    • All Quizzes
  • Therapy
    • Starting Therapy
    • Types of Therapy
    • Best Online Therapy Providers
    • Online Therapy Reviews & Guides
    • Mindfulness
  • Medication
    • Anxiety Medication
    • Depression Medication
    • ADHD Medication
    • All Psychotropic Medications
    • Best Online Psychiatrist Options
  • Reviews
    • Best Online Therapy
    • Best Online Therapy with Insurance
    • Best Online Therapy for Teens
    • Best Online Therapy for Anxiety
    • Best Online Therapy for Depression
    • Best Online ADHD Treatments
    • Best Online Psychiatry
    • Best Mental Health Apps
    • All Reviews
  • Therapy Worksheets
    • ADHD Worksheets
    • Anxiety Worksheets
    • Depression Worksheets
    • CBT Worksheets
    • DBT Worksheets
    • Therapy Worksheets for Kids
    • Therapy Worksheets for Teens
    • Relationship Worksheets
    • All Therapy Worksheets
  • About Us
    • About Us
    • Editorial Policy
    • Advertising Policy
    • Find a Local Therapist
    • Join Our Free Directory

Join our Newsletter

Get helpful tips and the latest information

Choosing Therapy on Facebook
Choosing Therapy on Instagram
Choosing Therapy on Twitter
Choosing Therapy on Linkedin
Choosing Therapy on Pinterest
Choosing Therapy on Tiktok
Choosing Therapy on Youtube
ChoosingTherapy.com Logo

Newsletter

Search Icon
  • Mental Health Issues
    • Anxiety
    • ADHD
    • Bipolar Disorder
    • Depression
    • Grief
    • Narcissism
    • OCD
    • Personality Disorders
    • PTSD
    • Anger
    • Burnout
    • Stress
  • Relationships
    • Dating
    • Marriage
    • Sex & Intimacy
    • Infidelity
    • Relationships 101
    • Best Online Couples Counseling Services
  • Quizzes
    • Anxiety Test
    • Depression Test
    • Burnout Test
    • All Quizzes
  • Therapy
    • Starting Therapy
    • Types of Therapy
    • Best Online Therapy Providers
    • Online Therapy Reviews & Guides
    • Mindfulness
  • Medication
    • Anxiety Medication
    • Depression Medication
    • ADHD Medication
    • All Psychotropic Medications
    • Best Online Psychiatrist Options
  • Reviews
    • Best Online Therapy
    • Best Online Therapy with Insurance
    • Best Online Therapy for Teens
    • Best Online Therapy for Anxiety
    • Best Online Therapy for Depression
    • Best Online ADHD Treatments
    • Best Online Psychiatry
    • Best Mental Health Apps
    • All Reviews
  • Therapy Worksheets
    • ADHD Worksheets
    • Anxiety Worksheets
    • Depression Worksheets
    • CBT Worksheets
    • DBT Worksheets
    • Therapy Worksheets for Kids
    • Therapy Worksheets for Teens
    • Relationship Worksheets
    • All Therapy Worksheets
  • About Us
    • About Us
    • Editorial Policy
    • Advertising Policy
    • Find a Local Therapist
    • Join Our Free Directory
  • What Is Psilocybin?What Is Psilocybin?
    • Is It Legal?Is It Legal?
  • How It WorksHow It Works
  • What Happens When IngestedWhat Happens When Ingested
  • Main EffectsMain Effects
  • Potential RisksPotential Risks
  • Possible BenefitsPossible Benefits
  • Medical UsesMedical Uses
    • Psilocybin TherapyPsilocybin Therapy
    • Self-MedicatingSelf-Medicating
  • What Is Microdosing?What Is Microdosing?
  • Is It Safe?Is It Safe?
  • Can You Become Addicted?Can You Become Addicted?
  • How To TryHow To Try
  • In My ExperienceIn My Experience
  • InfographicsInfographics
  • Additional ResourcesAdditional Resources
Substance Use Articles Substance Use Disorder Alcoholism Best Sobriety Apps Online MAT Programs

Psilocybin (Magic Mushrooms): Uses, Effects & Hazards

Headshot for John Cottone, PhD

Author: John Cottone, PhD

Headshot for John Cottone, PhD

John Cottone PhD

Dr. Cottone focuses on treating mood, anxiety, psychotic, and personality disorders in adults and adolescents. He integrates psychodynamic, family systems, and CBT with a special interest in meditation and Eastern philosophy.

See My Bio Editorial Policy
Headshot of Heidi Moawad, MD

Medical Reviewer: Heidi Moawad, MD Licensed medical reviewer

Headshot of Heidi Moawad, MD

Heidi Moawad MD

Heidi Moawad, MD is a neurologist with 20+ years of experience focusing on
mental health disorders, behavioral health issues, neurological disease, migraines, pain, stroke, cognitive impairment, multiple sclerosis, and more.

See My Bio Editorial Policy
Published: September 8, 2023 Updated: July 28, 2026
  • What Is Psilocybin?What Is Psilocybin?
    • Is It Legal?Is It Legal?
  • How It WorksHow It Works
  • What Happens When IngestedWhat Happens When Ingested
  • Main EffectsMain Effects
  • Potential RisksPotential Risks
  • Possible BenefitsPossible Benefits
  • Medical UsesMedical Uses
    • Psilocybin TherapyPsilocybin Therapy
    • Self-MedicatingSelf-Medicating
  • What Is Microdosing?What Is Microdosing?
  • Is It Safe?Is It Safe?
  • Can You Become Addicted?Can You Become Addicted?
  • How To TryHow To Try
  • In My ExperienceIn My Experience
  • InfographicsInfographics
  • Additional ResourcesAdditional Resources

Magic mushrooms (a.k.a. shrooms) are naturally occurring fungi whose primary compound, psilocybin, is converted into the mind-altering substance psilocin after ingestion.1 Psilocybin is a psychedelic drug that has long been known to induce perceptual alterations that can be mind-expanding but also disorienting. As such, psilocybin has recently received much attention for its potential medicinal and psychotherapeutic use.

ChoosingTherapy.com may earn a commission from the companies whose services are linked on this page.

ADVERTISEMENT

Experience the Proven Power of Psychedelic Therapy

Better U’s psychedelic-assisted therapy paves the way for profound healing and significant breakthroughs in well-being. Complete a free assessment so Better U can better understand your needs and ensure you receive a personalized treatment plan.

Start Your Free Assessment

What Is Psilocybin?

Psilocybin (3-[2-(dimethylamino) ethyl]-1H-indol-4-yl dihydrogen phosphate) is a naturally occurring compound found in over 200 different species of mushrooms. Ingestion of this hallucinogen can affect one’s perception, cognition, and mood. It has been used recreationally and medicinally throughout history, with vacillating legal status to this day.

Psilocybin can be sourced naturally – often from the dung of animals like cattle, horses, and buffalo – however, it can also be synthesized chemically. Regarding natural varietals, some of the most common types used for recreational and medicinal purposes are the psilocybe semilanceata (Liberty Caps) or psilocybe cubensis (Golden Teacher, White Albino, and Penis Envy) strains.

The experience after ingesting psilocybin is quite variable between people. When harvested (as opposed to synthesized in a laboratory), the amount of psilocybin per gram of mushroom can also vary substantially between and within species but is generally more stable in dried form than fresh.2,3,4

Are Magic Mushrooms Legal?

Since 1970, psilocybin has been classified as a Schedule I drug with other drugs, like heroin, that are deemed to have no recognized medicinal uses and a high potential for abuse. Legally, however, things began to change in 2018 when the FDA granted breakthrough therapy status to psilocybin for treatment-resistant depression.

Then, in 2020, the Entheogenic Plant and Fungus Policy Act was passed, which eased the enforcement laws for psychedelic drugs, including psilocybin, lowering its priority for law enforcement attention and prosecution.5 In addition, since 2020, several states have decriminalized psilocybin, including Oregon, Washington, California, Colorado, Michigan and Massachusetts.

Most recently, on June 23, 2023, the FDA issued guidance for clinical research using psilocybin (and also LSD and MDMA), allowing for legal use of psilocybin nationally within healthcare treatment settings with observation by two trained monitors, where one must be licensed with graduate-level professional training and clinical experience in psychotherapy.6

What Are the Different Forms of Psilocybin?

Psilocybin is available in many forms. Dried shrooms can be steeped in boiling water to form a tea or coated in chocolate to mask the bitter flavor. Fresh mushrooms contain 80-90% water and a greater quantity is thus needed per gram of psilocybin (depending on the strain). Mushrooms can also be ground into powder and sold in capsules; however, this form is considered less safe than fresh or dry since it can more easily be tampered with or laced with other substances.

What Is the Dose of Psilocybin in a Mushroom?

Intra- and inter-species variability is considerable regarding the actual amount of psilocybin in each mushroom specimen.2,3 Accordingly, one gram of mushroom can contain between 0.5% and 2% psilocybin; thus, starting out with smaller doses is recommended.1

On average, one gram of a dried mushroom from the Psilocybe cubensis species contains approximately 1% psilocybin. Most clinical research studies employ a 25mg dose of psilocybin, which would require ingestion of 2.5 grams of dried mushroom. A high dose would be 35mg of psilocybin, and a supra-therapeutic dose is 50-60mg.1

How Does Psilocybin Work?

Primarily, psilocin acts on serotonin, particularly at 5HT-2A receptor sites. However, it also indirectly influences other neurotransmitters, like glutamate, NMDA, and AMPA in the prefrontal cortex and dopamine in the striatum. This domino effect is believed to be responsible for psilocybin’s efficacy in treating several mental health disorders (e.g., depression and addiction), stimulating the creation of new neural connections, and improving cognitive function.7

When ingested, psilocybin is converted to psilocin (4-hydroxy-N,N-dimethyltryptamine) in the digestive tract, where the acidic environment aids the conversion. Unlike psilocybin, which is water-soluble and can’t cross the blood-brain barrier, its metabolite, psilocin, is fat-soluble and can make its way into the brain to trigger its psychotropic effects in 20-40 minutes, with peak effects in 60-90 minutes.

ADVERTISEMENT

Ketamine Therapy from the Comfort of Your Own Home

The expert clinical team at Better U offer an at-home Ketamine Therapy program that combines therapeutic guidance, safety protocols, breathwork, virtual treatment preparation, and 1-on-1 integration coaching. If you haven’t been satisfied by traditional medications or therapies, see if ketamine therapy is right for you.

Learn More

What Happens When You Take Magic Mushrooms?

As you interact with the world, your brain develops connections and pathways that strengthen the more they are used and reinforced. Psilocybin has been shown to be helpful in weakening dysfunctional connections that give rise to maladaptive thoughts and behavior – as with addiction, depression, and anxiety disorders (e.g., obsessive-compulsive disorder) – and encouraging new adaptive connections.9

Psilocybin affects the brain and body in the following ways:

  • Serotonin: Psilocybin’s metabolite, psilocin, which closely resembles serotonin, activates serotonin pathways, particularly mediated through 5HT-2A receptors. This contributes to direct effects, like the generation of psychedelic effects and hallucinations, and is believed to underlie psilocybin’s role in treating depression and suicidality.10
  • Glutamate: The flood of serotonin activity leads to a release of glutamate in the prefrontal cortex.10 Psilocin’s effect on prefrontal glutamate is believed to be central to its therapeutic role in treating addiction and improving cognition.7
  • Dopamine: Psilocin also indirectly increases the release of dopamine in the striatum via the changes in serotonin levels. Changes to striatal dopamine are believed to underlie psilocybin’s therapeutic effect for patients who suffer from depression with suicidal ideation and addiction since it regulates dysfunction in the reward pathway.10
  • Neural connectivity plasticity, neurogenesis: Psilocybin alters connections between neurons (plasticity) and stimulates new neuronal growth (neurogenesis) through activation of brain-derived neurotrophic factor (BDNF), which modulates N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in the prefrontal cortex. These changes can further affect gene expression and signal transduction.7
  • Oscillatory brain activity: Brain oscillations are rhythmic patterns in brain activity that reflect the ongoing communication between brain areas as you move through your day or sleep at night. Psilocybin calms certain oscillations (e.g., resting-state and default-mode network) while leaving others intact (e.g., basic visual and motor). Essentially, it can be conceived as an orchestra conductor, helping brain areas synchronize to create a more balanced symphony.11
  • Cerebral glucose metabolism: Cerebral glucose metabolism reflects how the brain uses energy and, essentially, how active it is. Psilocybin increases the regional cerebral glucose metabolism in the frontal cortex in a pattern similar to that observed during an acute psychotic episode.12
  • Antioxidant activity: Psilocybin has been shown to reduce oxidative stress in the brain and has been theorized to reduce suicidal behavior.10,13,14
  • Blood flow: Psilocybin decreases cerebral blood flow in key hub-like brain regions like the thalamus and cingulate.15 This is believed to play a role in the calming of existing neural connections, allowing alternative connections to form.16
  • Cardiovascular changes: Magic mushrooms contain other compounds besides psilocybin: Phenylethylamine (PEA) is an amphetamine-like compound that can cause adverse side effects like tachycardia and high blood pressure as well as anxiety and nausea in some people. It is more variable between mushroom specimens than psilocybin and may be the reason why some people experience worse side effects than others.17

What Are the Main Effects of Magic Mushrooms?

Though people take magic mushrooms with different goals in mind, the main effect is a series of alterations in mood, sensory perception, and psychological perspective, along with a dissociative trance state leading to the separation of a person from their ego. Researchers believe that the therapeutic effects of psilocybin and other psychedelics are largely absent when this dissociative trance is not achieved.18

Magic mushrooms or ‘shrooms’ can cause the following effects:

  • Feelings of euphoria
  • Altered thoughts
  • Seeing issues from a different perspective
  • Synesthesia (blending of senses like tasting colors or seeing sounds)
  • Improved cognition
  • Reduced suicidality
  • Reduced anxiety
  • Spiritual connectedness
  • Relief of existential distress
  • Mystical feelings
  • A cutting of the cord between one’s thoughts and emotions
  • Feeling no separation between the self and the environment, which some people experience as beautiful and others experience as terrifying
  • Altered perception of space and time
  • Dissociation
  • Dilated pupils
  • Anti-inflammatory effects

Physical Side Effects

It’s not uncommon for people to experience negative physical side effects – particularly stomach-related – after ingesting psilocybin mushrooms. These gastro symptoms, including stomach pain, nausea, and occasional vomiting, often present for about 15-20 minutes before the onset of psilocybin’s psychedelic effects. It has been suggested that such side effects are not induced by the psilocybin itself but rather by other compounds in the fungus (e.g., phenylethylamine) and their interaction with stomach acids.4,17

Common physical side effects of psilocybin include:

  • Nausea
  • Transient hypertension
  • Increased heart rate (tachycardia)
  • Mild headache
  • Muscle weakness

Less common physical side effects of psilocybin include:

  • Physical discomfort
  • Vomiting
  • Fatigue

Negative Mental & Emotional Effects

Not every psilocybin trip will be experienced in a pleasurable or positive way. An estimated 9% of psychedelic users (slightly lower for psilocybin) will have a distressing experience leading to functional impairment lasting more than a day.19

Some negative mental effects can result from some powerful or unexpected sensations that result. Others may stem from feelings of dissociation or ego death that are too disorienting. And yet others may be the result of anxiety that manifests – either in direct or indirect response to the mental effects of the trip.

Common mental and emotional effects of psilocybin include:

  • Perceptual distortions
  • Nervousness
  • Anxiety
  • Confusion

Less common mental and emotional effects of psilocybin include:

  • Hallucinations
  • Paranoia
  • Intense fear
  • Mental discomfort
  • Prolonged psychosis

Does Everyone Experience the Effects of Psilocybin Similarly?

The nature of each psilocybin experience can vary based on many factors, including one’s personality, biology, and mindset. While some biological factors like genetics, susceptibility to psychosis, and medical contraindications can skew the experience, psychological factors like mindset can play a role, too.

Factors that can influence your experience with mushrooms include:

  • Set: Factors brought into the experience by the individual, like one’s drug sensitivity, previous experiences, expectations, and mental state
  • Setting: Physical and social environment in which the drug is taken (e.g., serene retreat center or a loud dance club; music, religious or spiritual imagery; presence of support staff)
  • Guide/Support: Having a trusted sober person (e.g., a therapist, guide, or friend) to stay with you and support you through the experience can reduce anxiety before and during.
  • Stomach acidity: Greater stomach acidity can increase the metabolism of psilocybin to its active metabolite, psilocin.7 Some users have reported that mixing the shroom powder with lemon juice before ingesting it (called lemon tekking) can speed up the psychotropic effects, but this can also increase the side effects as well.
  • Empty stomach: The amount of food one has in the stomach and the degree to which that food is fat-soluble can affect the metabolism of psilocybin. Research and clinical applications of psilocybin usually require fasting for 1-2 hours before ingestion.1
  • Liver dysfunction: Since some conversion of psilocybin to psilocin occurs in the liver, dysfunction of this organ may change the experience.
  • Prior psychedelic use: Recent use of psilocybin and other psychedelics (e.g., LSD) can raise one’s tolerance, resulting in reduced psychotropic effects.
  • Purity and species/strain of the psilocybin: Synthetic psilocybin from a licensed laboratory has the highest purity. Naturally harvested fresh and dried mushrooms can vary substantially between and even within a given species and strain.
  • Method of administration: Effects are first experienced around 40 minutes after oral ingestion of psilocybin and 4 minutes after intravenous administration. However, the effects last for 4-6 hours after oral administration and only 45-60 minutes after intravenous.10
  • Age: While psilocybin has shown promise as a therapeutic for end-of-life anxiety and other conditions like dementia, most research studies have not included participants over the age of 60, so safety and efficacy for older adults is not well studied. Side effects like cardiovascular events are of particular concern.20
  • Body weight and metabolism: While body weight does not seem to affect the subjective effects of a given psilocybin dosage, metabolism (how efficiently your body processes and breaks down the psilocybin) can.21,22
  • Personality: Personality types that are most conducive to a positive experience are those that are not prone to anxiety. However, psilocybin can also alter certain facets of personality; for example, it was shown to reduce a person’s neuroticism and increase extraversion and conscientiousness at 3 months following treatment.23
  • Contraindications: There are several conditions that increase the likelihood of a negative experience, including schizophrenia, psychosis, bipolar disorder, borderline personality disorder, and cardiovascular conditions.

ADVERTISEMENT

Experience the Proven Power of Psychedelic Therapy

Better U’s psychedelic-assisted therapy paves the way for profound healing and significant breakthroughs in well-being. Complete a free assessment so Better U can better understand your needs and ensure you receive a personalized treatment plan.

Start Your Free Assessment

Potential Risks of Magic Mushrooms

Psilocybin is not recommended for individuals at risk for psychosis, schizophrenia, bipolar disorder, or borderline personality disorder, as it can increase the risk of psychological distress and psychotic symptoms. It is also not recommended for people who are pregnant or breastfeeding, as there is a lack of safety data.1

Physical risks include increases in blood pressure and heart rate and stress on liver function. Accordingly, psilocybin may be contraindicated for individuals with cardiac and liver conditions.

Some of the risks of taking magic mushrooms include:

Bad Trips

While many people have a positive experience when taking magic mushrooms, an estimated 30%-40% of individuals experience a “bad trip,” characterized by distressing feelings of fear, panic, and paranoia and somatic symptoms like heart palpitations and dizziness.24,25 A common theme of a bad trip involves “ego dissolution” (a.k.a., “ego death”) or a sense of one’s individuality vanishing, though some people experience this state as a spiritually blissful oneness with the universe.

Ironically, despite the distress caused by a “bad trip,” many of the individuals (80%) experiencing a bad trip also report improvement in well-being afterward and have found therapeutic benefits to the challenging experience.26

Several factors that can contribute to a bad trip include:

  • Pre-existing mental health conditions (e.g., disorders involving psychosis)
  • Dosage (higher doses are more likely to lead to negative experiences)
  • Impurity of the substance being ingested
  • Anxiety before the session starts
  • Unfamiliar environment
  • Threatening environment
  • Unsupportive people around you
  • Unresolved emotional conflict

Mushroom Poisoning/Overdose

According to research studies, 25mg is considered a standard dose, 35mg a high dose, and 50-60mg a supra-therapeutic dose. Overdosing on psilocybin is not likely as it has a favorable safety profile with an extremely high lethal dose. However, higher doses can increase the likelihood of side effects, especially in drug-naive individuals and those with cardiovascular contraindications.27,28

Given psilocybin’s relatively safe profile (especially compared with other psychedelics like MDMA and DMT), the larger concern is accidental poisoning from incorrectly identified mushroom species. Since psilocybin is currently not legal in many areas, individuals seeking to consume magic mushrooms for recreational or medicinal purposes may procure it from unreputable sources and risk accidentally ingesting a poisonous fungus species with a similar appearance.29

Drug Interactions

Research findings related to interactions between psilocybin and other psychoactive drugs are limited, and much of what is known is theoretical. Much of the existing research focuses on the 5HT2A receptor, which, when blocked by psychiatric medications like buspirone, risperidone, ketanserin, or chlorpromazine, seems to weaken psilocybin’s psychedelic effects. However, there doesn’t appear to be an observable interaction between psilocybin and serotonin agonists, like ergotamine, or dopamine antagonists, like haloperidol.30

Potential Benefits of Magic Mushrooms

There are few large studies examining the efficacy of magic mushrooms relative to traditional psychiatric medications. However, existing research does indicate some notable benefits for mushrooms over traditional treatments.

Psilocybin may offer benefits more medicinal in nature, including:

  • Multiple mechanisms of action: Psilocybin mushrooms work on multiple neurotransmitters in the brain across multiple neural networks, which gives them the potential to treat multiple aspects of human functioning and, thus, multiple psychological conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD), to name a few.
  • Low potential for abuse: There is little to no evidence of physical dependence or withdrawal from psilocybin.
  • Few side effects: Psilocybin’s few adverse effects are mild in many (but not all) cases, like transient hypertension, tachycardia, and headaches; however, prolonged psychosis, though rare, is possible.31
  • Works relatively quickly: Relative to many traditional psychiatric medications, and especially SSRIs, psilocybin works quickly, with peak effects occurring within 90 minutes of ingestion. Relative to other psychedelics, psilocybin shows faster elimination (its half-life is about three hours) but with longer therapeutic effects.32
  • Few sessions are required: Since psilocybin builds up tolerance after just a few repeated uses, the number of sessions is necessarily limited and should be spaced out. Most therapeutic effects are observed after just a few sessions and sometimes even a single session (depending on the condition being treated).
  • Medication compliance is not an issue: A common hurdle for psychiatric medications and weekly psychotherapy is patient compliance. Since psychedelic-assisted therapy does not require a structured regimen to stick to, it may be a low-maintenance therapeutic option for individuals who struggle to adhere to routine.

Medical Uses for Psilocybin

In most states, psilocybin’s current status as a Schedule I drug prohibits its medical use outside of clinical research studies. Given the significant interest in research into psilocybin’s therapeutic effects, extraction of psilocybin from natural or cultivated mushrooms is too limited and variable to meet current research needs. As such, efforts to improve the synthetic creation of psilocybin, which began in the 1950s, are underway to increase yields, purity, and financial efficiency.33

Disorders that can potentially be treated by magic mushrooms and other psychedelics include:

  • Addiction: While studies have shown promising results for the treatment of nicotine and alcohol addiction, there are presently many ongoing studies examining efficacy and safety parameters for treating other substance and behavioral addictions that have not yet concluded.34
  • Smoking cessation: Psilocybin-assisted treatment for tobacco addiction had success rates (80% abstinence at 6-month follow-up, 67% abstinence at 1-year follow-up) that exceeded those reported for other treatment methods like psychotherapy and medication (commonly less than 35%).35,36
  • Alcohol use disorder (AUD): When combined with psychotherapy (motivational enhancement therapy or cognitive behavioral therapy), psilocybin can help with alcohol addictions. Research shows that two psilocybin treatment sessions resulted in reduced craving and alcohol consumption (27-41% fewer days) extending to at least 32 weeks.37,38 Although the results for AUD aren’t as robust as for smoking cessation, psilocybin may still be worthwhile as an add-on therapy for treatment-resistant individuals.
  • Methamphetamine use disorder: Ongoing studies are investigating whether psychedelics can be useful in treating methamphetamine use disorder, but results are not yet available. Given notably high drop-out rates for methamphetamine treatment and the success rate of psychedelics with other substance use disorders, psilocybin provides a potential treatment alternative.39
  • Other substance use disorders: There are currently no completed clinical trials on the efficacy of psilocybin-assisted therapy for many substances of misuse, including cocaine, hypnotics, and caffeine, to name a few.40 However, clinical trials should yield some results over the next couple of years. Given preliminary results with other addictive substances like nicotine, there is great interest in psilocybin’s potential for other types of substance misuse.
  • Non-substance addictions: As with many substance addictions, there is reason to believe that psilocybin may show potential as a treatment for non-substance addictions like gambling addiction, food addiction, and sex addiction, since it does modulate areas of the brain involved in reward processing and specifically, craving.36,40 However, the resurgence of this line of research is young, and preliminary clinical trials are still ongoing.
  • Eating disorders: Psilocybin-assisted psychotherapy improved shape concerns, weight concerns, and eating disorder scores for at least three months in 40% of the study participants, though the sample was small in this pilot study.41 Given relatively high comorbidity rates with other disorders that psychedelic treatment has shown efficacy for (e.g., depression, substance use disorder), this mode of treatment as an add-on therapy may be a feasible alternative treatment for eating disorders.
  • Alzheimer’s disease: As with many diseases, clinical trials for psychedelic-assisted treatment for Alzheimer’s disease are still ongoing, and it is premature to determine its efficacy for this population.42 Nonetheless, several studies showing increased brain activation and generation of new neural connections certainly carry much interest for potential use in dementia and other cognitive disorders, particularly in early phases.43
  • Treatment-resistant depression: A single dose of psilocybin-assisted therapy reduced symptom severity in a study of 52 participants with treatment-resistant depression.44 Even at a one-year follow-up, a similar study showed symptom improvement in 75% of participants and remission in 58%.45
  • Obsessive compulsive disorder (OCD): Despite small samples for recent studies on psilocybin and OCD, one case study and another nine-person, the treatment-resistant sample showed marked symptom relief lasting 24 hours up to 6 months post-treatment.46 The case report of a patient described how he not only found remission of symptoms with a single dose of psilocybin, but years later, when symptoms returned, he was able to use insights obtained during the psilocybin treatment to improve his symptoms.47
  • Headaches: Paradoxically, while transient headaches are an occasional side effect of psilocybin, it has also been shown to help treat migraines and cluster headaches, particularly regarding symptom frequency, intensity, impairment, and prevention.148,49,50,51 More research is needed to untangle this interesting paradox.
  • Chronic pain: Case studies have described sustained relief of chronic neuropathic pain with psilocybin micro-dosing and without any psychedelic (mind-altering) experience.52 Pain relief in other conditions like phantom limb syndrome has also been augmented with psilocybin treatment, possibly due to neuroplasticity properties.53
  • End-of-life distress: High-dose psilocybin appears to significantly reduce anxiety for individuals with life-threatening cancer and cancer-related depression and anxiety, with effects lasting at least six months after treatment and in one study, nearly five years after treatment.54

Psilocybin Therapy

Given the current legal hurdles to obtaining psilocybin therapy outside of a clinical research trial or a state where psilocybin use has been decriminalized, treatment is still impractical and often expensive. For those who can receive psilocybin treatment, numerous benefits await. The first is speed, as even a single session has shown significant efficacy for certain conditions.

Here are some questions to ask a therapist who specializes in psilocybin therapy:

  • What type of therapeutic style do you use in conjunction with psilocybin?
  • Will you have several sessions before incorporating psilocybin into treatment to build a trusting relationship?
  • Are we going to prepare a plan in advance with topics to address?
  • Do I have any medical conditions or risk factors that would be contraindicated for psilocybin use?
  • What should I do in preparation?

Self-Medicating With Shrooms

Because of how expensive psilocybin therapy is, there has been an uptick in reports of self-medicating with shrooms.60 If you are planning to use shrooms therapeutically in an uncontrolled environment, there are several things you will want to consider to increase the likelihood of a successful outcome and reduce your risk of harm.

Here are some things to consider when exploring psilocybin in an uncontrolled environment:

  • Do you have a support person or guide to ensure you stay safe while in an altered state? It is extremely important to ensure that you have someone who is sober and can help you or get help should you experience negative side effects that need medical attention.
  • Where are the mushrooms sourced? Be sure it is from a reputable and trusted source, preferably a licensed medical provider (pending legality in some areas). If you don’t live in an area where psilocybin is approved for medical use, consider a retreat in a region where it can be sourced from a licensed and reputable establishment.
  • Which strain and expected potency will you be ingesting? The wide variety of strains and potencies can offer very different types of experiences and come with varying risks of a bad trip.
  • Will you have the right amount of time? Be sure you don’t have responsibilities (occupational, child care, etc.) that will need your attention for a couple of hours leading up to ingestion, as well as for the rest of the day after ingestion. Driving, operating machinery, and related activities can be highly dangerous while under the influence of psilocybin, and some effects can linger, especially if you are unaware of a contraindication (e.g., a family history of schizophrenia).
  • Where will you be ingesting psilocybin? Be sure you are in a safe, relaxed, calm setting. The mood and ambiance can play a significant role in how pleasurable the treatment is.
  • How are you preparing? Fasting is often recommended prior to optimal effects. There are also anti-nausea strategies that can help reduce side effects.

What is Microdosing?

Psilocybin microdosing involves repeated self-administration of small doses that do not affect regular cognitive functioning or induce acute psychotropic symptoms. Sometimes using psilocybin for anxiety can help. Research studies show that the intake of psilocybin microdoses can improve mood, cognitive function, anxiety, depression, and experience of stress after one month.55

While dosing is variable as this is not a formal medical practice, a typical microdose is between 0.1g-0.3g of dried mushrooms which translates to 1mg-3mg of psilocybin.55 For perspective, a standard dose to induce mind-altering effects is 25mg. With incorporation as a medicinal therapeutic and unfolding legislative changes, psilocybin microdosing may be a viable treatment option in the future for mood and anxiety disorders.

Is Psilocybin Safe?

Despite having been listed as a Schedule I controlled substance since 1970, psilocybin actually has a low abuse potential, and withdrawal effects have not been documented to date.56 While psilocybin itself is relatively safe when used in a licensed medical or therapeutic setting, it can be unsafe when procured from unregulated or illegal sources, used by people with certain mental health and medical conditions, or used in combination with other drugs and/or medications.

Can You Become Addicted to Psychedelic Mushrooms?

Even though psilocybin does not seem to be addictive, one can build up a tolerance with repeated use, needing a higher dosage to achieve the same effect, with the mental effects capping after four consecutive doses. Therefore, individuals who find the mind-altering effects pleasurable – particularly the feelings of dissociation it induces – may grow psychologically dependent and show limited motivation for doing anything besides using. Also, procuring psilocybin from a questionable source can also introduce the risk of it being laced with other drugs of misuse that may be addictive.

Getting Help For Psilocybin Misuse

Psilocybin has shown therapeutic potential for individuals diagnosed with substance use disorder (e.g., alcohol, nicotine) when combined with psychotherapy, and it doesn’t seem to hold a significant risk of addiction.39,59 Nonetheless, misuse is possible when a person uses magic mushrooms too frequently, prefers its intoxicated state over sobriety, uses increasingly larger doses to achieve the same effect, and/or struggles to refrain from use when it interferes with daily functioning.

If you or someone you care about is misusing psilocybin, psychotherapy can help to identify the underlying causes of misuse and its correlates. It can also be beneficial to discuss the risks involved with unregulated sources (e.g., misidentification of a poisonous specimen) and why they are choosing to use the substance.

Here are some signs that someone may be misusing psilocybin:

  • Dissociative states
  • Depersonalization
  • Derealization
  • Illogical thinking
  • Dangerous behavior
  • Withdrawal from relationships
  • Desires for radical change
  • Rapid change to one’s life goals
  • Existential depression

How Can I Try Psilocybin-Assisted Therapy?

While psilocybin and other psychedelics (e.g., ketamine) are illegal in many areas, there is a burgeoning of clinical research studies that are seeking participants. Government-approved research will use reputably sourced psilocybin with reliable purity. You can search the government’s clinical trials database for enrollment opportunities. Alternatively, there are therapists who specialize in psychedelic therapy, who can guide you through applying for a study, as well as supply you with supplementary therapy to make the most of your treatment.

If you need help finding a therapist, an online therapist directory or online therapy platform can be a useful starting point.

ADVERTISEMENT

Ketamine Therapy from the Comfort of Your Own Home

The expert clinical team at Better U offer an at-home Ketamine Therapy program that combines therapeutic guidance, safety protocols, breathwork, virtual treatment preparation, and 1-on-1 integration coaching. If you haven’t been satisfied by traditional medications or therapies, see if ketamine therapy is right for you.

Learn More

In My Experience

Psilocybin is a drug that offers promise to treat a wide range of physical and psychological conditions. Though clinical research trials investigating its efficacy and safety are still few, the research that does exist, combined with centuries of anecdotal reports of its medicinal benefits from indigenous peoples, suggests that psilocybin can be used safely, under supervised conditions, with minimal adverse effects.

The psychedelic effects of psilocybin – particularly the dissociation that it induces – aren’t for everyone, and it shouldn’t be considered until other traditional treatments have been tried. However, for those who may be candidates, psilocybin can offer a beneficial therapeutic experience, particularly when paired with psychotherapy.

Though other forms of therapy, like cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT), have been paired successfully with psychedelic treatments, psychodynamic therapy is ideal for pairing with psilocybin treatment as it regularly involves an assessment of the unconscious elements that typically manifest during psilocybin use.

Remember that, like psychotherapy, just because a psilocybin experience is uncomfortable, it doesn’t mean a positive transformation can’t result. A patient of mine summed this up perfectly, saying this about a recent trip: “I either fixed something that needed to be fixed, or I broke something that needed to be broken.”

Headshot for John Cottone, PhD John Cottone, PhD

Psilocybin (Magic Mushrooms) Infographics

What Is Psilocybin? Are Magic Mushrooms Legal? Potential Benefits of Magic Mushrooms Medical Uses for Psilocybin  What is Microdosing?

Sources Update History

ChoosingTherapy.com strives to provide our readers with mental health content that is accurate and actionable. We have high standards for what can be cited within our articles. Acceptable sources include government agencies, universities and colleges, scholarly journals, industry and professional associations, and other high-integrity sources of mental health journalism. Learn more by reviewing our full editorial policy.

  • MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022). Therapeutic use of psilocybin: Practical considerations for dosing and administration. Frontiers in Psychiatry, 13, 1040217.

  • Beug, M. W., & Bigwood, J. (1982). Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, USA. Journal of ethnopharmacology, 5(3), 271-285.

  • Bigwood, J., & Beug, M. W. (1982). Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer. Journal of Ethnopharmacology, 5(3), 287-291.

  • Van Amsterdam, J., Opperhuizen, A., & van den Brink, W. (2011). Harm potential of magic mushroom use: a review. Regulatory toxicology and pharmacology, 59(3), 423-429.

  • Chapter 9C. Entheogenic plant and fungus policy. D.C. Law Library. (n.d.). https://code.dccouncil.gov/us/dc/council/code/titles/48/chapters/9C

  • Commissioner, O. of the. (n.d.). FDA issues First Draft Guidance on clinical trials with psychedelic drugs. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs

  • Ziff, S., Stern, B., Lewis, G., Majeed, M., & Gorantla, V. R. (2022). Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. Cureus, 14(2).

  • Nichols, D. E. (2020). Psilocybin: From ancient magic to modern medicine. The Journal of antibiotics, 73(10), 679-686.

  • Petri, G., Expert, P., Turkheimer, F., Carhart-Harris, R., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks. Journal of The Royal Society Interface, 11(101), 20140873.

  • Strumila, R., Nobile, B., Korsakova, L., Lengvenyte, A., Olie, E., Lopez-Castroman, J., … & Courtet, P. (2021). Psilocybin, a naturally occurring indoleamine compound, could be useful to prevent suicidal behaviors. Pharmaceuticals, 14(12), 1213.

  • Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe, D., … & Nutt, D. J. (2013). Broadband cortical desynchronization underlies the human psychedelic state. Journal of Neuroscience, 33(38), 15171-15183.

  • Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Maguire, P., Stadelmann, O., & Angst, J. (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology, 16(5), 357-372.

  • Karbownik, M., Gitto, E., Lewiñski, A., & Reiter, R. J. (2001). Relative efficacies of indole antioxidants in reducing autoxidation and iron‐induced lipid peroxidation in hamster testes. Journal of cellular biochemistry, 81(4), 693-699.

  • Estevão, M. S., Carvalho, L. C., Ribeiro, D., Couto, D., Freitas, M., Gomes, A., … & Marques, M. M. B. (2010). Antioxidant activity of unexplored indole derivatives: Synthesis and screening. European Journal of Medicinal Chemistry, 45(11), 4869-4878.

  • Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., … & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143.

  • Milliken, E., Galettis, P., & Martin, J. (2023). A review of psilocybin: chemistry, clinical uses and future research directions. Australian Journal of Chemistry.

  • Beck, O., Helander, A., Karlson-Stiber, C., & Stephansson, N. (1998). Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions. Journal of analytical toxicology, 22(1), 45-49.

  • Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., … & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of psychoactive drugs, 51(2), 189-198.

  • Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2023). Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. Journal of Affective Disorders, 326, 105-110.

  • Johnston, C. B., Mangini, M., Grob, C., & Anderson, B. (2023). The safety and efficacy of psychedelic-assisted therapies for older adults: knowns and unknowns. The American Journal of Geriatric Psychiatry, 31(1), 44-53.

  • Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2021). Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology, 35(4), 353-361.

  • Dinis-Oliveira, R. J. (2017). Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug metabolism reviews, 49(1), 84-91.

  • Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica, 138(5), 368-378.

  • Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 218, 649-665.

  • Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187, 268-283.

  • Gashi, L., Sandberg, S., & Pedersen, W. (2021). Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy, 87, 102997.

  • Li, S., Ma, Q. B., Tian, C., Ge, H. X., Liang, Y., Guo, Z. G., … & Riley, F. (2019). Cardiac arrhythmias and cardiac arrest related to mushroom poisoning: A case report. World journal of clinical cases, 7(16), 2330.

  • Borowiak, K. S., Ciechanowski, K., & Waloszczyk, P. (1998). Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. Journal of Toxicology: Clinical Toxicology, 36(1-2), 47-49.

  • Lincoff, G., & Mitchel, D. H. (1977). Toxic and hallucinogenic mushroom poisoning. A handbook for physicians and mushroom hunters. Van Nostrand Reinhold Company.

  • Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022). Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology, 239(6), 1945-1976.

  • Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). R agonist psilocybin in the treatment of tobacco addiction 2A pilot study of the 5-HT on behalf of: British association for psychopharmacology can be found at: Journal of psychopharmacology Additional services and information for. Downloaded from Journal of Psychopharmacology, 12(10), 983-992.

  • Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143-166.

  • Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., … & Gordon, L. (2021). The therapeutic potential of psilocybin. Molecules, 26(10), 2948.

  • CTG Labs – NCBI. (n.d.). https://clinicaltrials.gov/

  • Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of psychopharmacology, 28(11), 983-992.

  • Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse, 43(1), 55-60.

  • Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of psychopharmacology, 29(3), 289-299.

  • Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., … & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA psychiatry, 79(10), 953-962.

  • Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., … & Stauffer, C. S. (2023). Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Frontiers in Psychiatry, 14, 412.

  • Van Der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., … & Batalla, A. (2023). Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in Psychiatry, 14, 1134454.

  • Peck, S. K., Shao, S., Gruen, T., Yang, K., Babakanian, A., Trim, J., … & Kaye, W. H. (2023). Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nature Medicine, 1-7.

  • Carter, A., Graham, M., Hall, W., Barber, M., & Gardner, J. (2023). Avoiding the Premature Introduction of Psychedelic Medicines in Alzheimer’s Disease and Related Disorders. AJOB neuroscience, 14(2), 129-131.

  • Sarangi, A., & Akinkunmi, O. (2023). Psychedelics for the Neuropsychiatric Symptoms of Alzheimer’s disease. The American Journal of Geriatric Psychiatry, 31(3), S44-S45.

  • Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., … & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry, 78(5), 481-489.

  • Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151-158.

  • Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of clinical Psychiatry, 67(11), 1735-1740.

  • Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G., Ching, T. H., Belser, A., & Pittenger, C. (2022). Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon, 8(12).

  • Johnson, M. W., Sewell, R. A., & Griffiths, R. R. (2012). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug and alcohol dependence, 123(1-3), 132-140.

  • Schindler, E. A., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H., … & D’Souza, D. C. (2021). Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics, 18(1), 534-543.

  • Andersson, M., Persson, M., & Kjellgren, A. (2017). Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches. Harm reduction journal, 14, 1-10.

  • Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920-1922.

  • Lyes, M., Yang, K. H., Castellanos, J., & Furnish, T. (2022). Microdosing psilocybin for chronic pain: a case series. Pain, 10-1097.

  • Ramachandran, V., Chunharas, C., Marcus, Z., Furnish, T., & Lin, A. (2018). Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase, 24(2), 105-110.

  • Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., … & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155-166.

  • Rootman, J. M., Kiraga, M., Kryskow, P., Harvey, K., Stamets, P., Santos-Brault, E., … & Walsh, Z. (2022). Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Scientific Reports, 12(1), 11091.

  • De Veen, B. T., Schellekens, A. F., Verheij, M. M., & Homberg, J. R. (2017). Psilocybin for treating substance use disorders?. Expert review of neurotherapeutics, 17(2), 203-212.

  • Buchborn, T., Grecksch, G., Dieterich, D. C., & Höllt, V. (2016). Tolerance to lysergic acid diethylamide: overview, correlates, and clinical implications. Neuropathology of Drug Addictions and Substance Misuse, 846-858.

  • Kooijman, N. I., Willegers, T., Reuser, A., Mulleners, W. M., Kramers, C., Vissers, K. C., & van Der Wal, S. E. (2023). Are psychedelics the answer to chronic pain: A review of current literature. Pain Practice, 23(4), 447-458.

  • Sharma, R., Batchelor, R., & Sin, J. (2023). Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. Journal of Psychoactive Drugs, 1-19.

  • Matzopoulos, R., Morlock, R., Morlock, A., Lerer, B., & Lerer, L. (2022). Psychedelic mushrooms in the USA: Knowledge, patterns of use, and association with health outcomes. Frontiers in Psychiatry, 12, 780696.

Show more Click here to open the article sources container.

We regularly update the articles on ChoosingTherapy.com to ensure we continue to reflect scientific consensus on the topics we cover, to incorporate new research into our articles, and to better answer our audience’s questions. When our content undergoes a significant revision, we summarize the changes that were made and the date on which they occurred. We also record the authors and medical reviewers who contributed to previous versions of the article. Read more about our editorial policies here.

July 28, 2026
Author: ChoosingTherapy.com Editorial Team
Primary Changes: Link maintenance: removed 5 links that no longer pointed to live resources.
Show more Click here to open the article update history container.

Your Voice Matters

Can't find what you're looking for?

Request an article! Tell ChoosingTherapy.com’s editorial team what questions you have about mental health, emotional wellness, relationships, and parenting. Our licensed therapists are just waiting to cover new topics you care about!

Request an Article

Leave your feedback for our editors.

Share your feedback on this article with our editors. If there’s something we missed or something we could improve on, we’d love to hear it.

Our writers and editors love compliments, too. :)

Leave Feedback

Additional Resources

To help our readers take the next step in their mental health journey, ChoosingTherapy.com has partnered with leaders in mental health and wellness. ChoosingTherapy.com is compensated for marketing by the companies included below.

Online Therapy 

BetterHelp – Get support and guidance from a licensed therapist. BetterHelp has over 30,000 therapists who provide convenient and affordable online therapy. BetterHelp starts at $65 per week and is FSA/HSA eligible by most providers. Take a free online assessment and get matched with the right therapist for you. Free Assessment

Therapy & Medication Using Your Insurance

Brightside Health – Together, medication and therapy can help you feel like yourself, faster. Brightside Health treatment plans start at $95 per month. United Healthcare, Anthem, Cigna, and Aetna accepted. Following a free online evaluation and receiving a prescription, you can get FDA approved medications delivered to your door. Free Assessment

Tips for Starting Therapy Newsletter

A free newsletter from the experts at ChoosingTherapy.com for those interested in learning about therapy and how to get the most benefits out of therapy. Get helpful tips and the latest information. Sign Up

ChoosingTherapy.com Directory 

Find local therapists that offer online and in-person therapy. Search for therapists by specialty, experience, insurance, and location. Find a therapist near you.

Best Online Therapy Services of 2025: Our Firsthand Experiences & Recommendations

Best Online Therapy Services

There are a number of factors to consider when trying to determine which online therapy platform is going to be the best fit for you. It’s important to be mindful of what each platform costs, the services they provide you with, their providers’ training and level of expertise, and several other important criteria.

Read More

Best Online Psychiatry Services

Best Online Psychiatry Services

Online psychiatry, sometimes called telepsychiatry, platforms offer medication management by phone, video, or secure messaging for a variety of mental health conditions. In some cases, online psychiatry may be more affordable than seeing an in-person provider. Mental health treatment has expanded to include many online psychiatry and therapy services. With so many choices, it can feel overwhelming to find the one that is right for you.

Read More

ChoosingTherapy.com Logo White
  • About Us
  • Contact Us
  • Write for Us
  • Careers
  • Editorial Policy
  • Advertising Policy
  • Privacy Policy
  • Terms of Service

FOR IMMEDIATE HELP CALL:

Medical Emergency: 911

Suicide Hotline: 988

View More Crisis Hotlines
Choosing Therapy on Facebook
Choosing Therapy on Instagram
Choosing Therapy on X
Choosing Therapy on Linkedin
Choosing Therapy on Pinterest
Choosing Therapy on Tiktok
Choosing Therapy on Youtube

© 2025 Choosing Therapy, Inc. All rights reserved.

X